Vertex PharmaceuticalsWBO:VRTX +2.43%90 PB Ratio is 6.37 as of Jun. 24, 2026, which is 14% below its 10-year median of 7.37. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €439.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 76.16% on this metric.
The historical rank and industry rank for Vertex Pharmaceuticals's PB Ratio or its related term are showing as below:
WBO:VRTX'
s PB Ratio Range Over the Past 10 Years
Min: 4.81 Med: 7.37 Max: 25.85
Current: 6.3
During the past 13 years, Vertex Pharmaceuticals's highest PB Ratio was 25.85. The lowest was 4.81. And the median was 7.37.
WBO:VRTX's PB Ratio is ranked worse than 76.16% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs WBO:VRTX: 6.30
During the past 12 months, Vertex Pharmaceuticals's average Book Value Per Share Growth Rate was 18.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 36.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vertex Pharmaceuticals was 97.50% per year. The lowest was -58.90% per year. And the median was 15.10% per year.
Back to Basics: PB Ratio
Vertex Pharmaceuticals (WBO:VRTX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vertex Pharmaceuticals (WBO:VRTX) has a PB Ratio of 6.37 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vertex Pharmaceuticals and its competitors. This is 14% below median its historical median of 7.37. Over the past decade, Vertex Pharmaceuticals' PB Ratio has ranged from 4.81 to 25.85. According to the industry distribution chart, Vertex Pharmaceuticals ranks #939 out of 1233 companies in the Biotechnology industry, placing it in the top 76.2%.
Is Vertex Pharmaceuticals' PB Ratio too high?
Vertex Pharmaceuticals' current PB Ratio of 6.37 is 14% below median its 10-year median of 7.37. Over the past 10 years, this metric has ranged from a low of 4.81 to a high of 25.85. The Biotechnology industry median PB Ratio is 2.83. Vertex Pharmaceuticals' value of 6.37 is 125.1% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #939 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' PB Ratio compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #939 out of 1233 companies for PB Ratio. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.83. Vertex Pharmaceuticals' value of 6.37 is 125.1% above this benchmark. Historically, Vertex Pharmaceuticals' own PB Ratio has ranged from 4.81 to 25.85 over the past decade. While the company's 10-year median is 7.37 vs. the industry median of 2.83, Vertex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current PB Ratio of 6.37 is 125.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current PB Ratio is 6.37, which is 14% below median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.78, compared to a current price of €420.05 — trading 4.5% below its estimated fair value. The current PB Ratio is 6.37, which is 14% below median its 10-year median of 7.37 and 125.1% above the Biotechnology industry median of 2.83. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current PB Ratio is 6.37 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of €420.05 is trading 4.5% below its estimated GF Value™ of €439.78.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for WBO:VRTX:
PB Ratio: 6.37 (14% below median its 10-year median of 7.37)
GF Value™: €439.78 vs. price of €420.05 (4.5% below fair value)
Industry Position: 125.1% above the Biotechnology median (#939 of 1233)
No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score
Get the complete analysis for WBO:VRTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VRTX has been successfully added to your 
